Navigation Links
How did glycine significantly decrease liver injury?
Date:10/31/2008

The nonessential amino acid glycine has been shown to be anti-inflammatory in several animal injury models. Recent studies demonstrated that dietary glycine protected both the lung and liver against lethal doses of endotoxin in rat or other animals and improved graft survival after liver transplantation. The influence of dietary glycine on oxidant-induced or cholestatic liver injury was not known.

A research article to be published on October 21, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Prof. Thurman from the University of North Carolina used a dietary and cholestatic model thru BDL in rats to address this question. They could demonstrate that hepatic injury due to BDL is significantly reduced by dietary glycine in rats. Moreover, the data indicated that glycine decreases liver injury under the conditions of experimental cholestasis thru a direct effect on hepatocytes. Surprisingly, Kupffer cells did not appear to play a major role in the pathological changes caused by cholestasis.

It is best known that Kupffer cells, the resident macrophages of the liver, are involved in several disease states, such as endotoxin shock, alcoholic liver diseases, and other toxicant-induced liver injury by releasing eicosanoids, inflammatory cytokines, and free radical species. Furthermore, in previous studies of the research team, a glycine-dependent chloride channel on the cell membrane of Kupffer cells and other macrophages that influence the activation process of these cells could be detected. But in the actual used cholestatic model no significant influence of this cell line on liver injury could be detected.


'/>"/>

Contact: Lin-Lin Xiao
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. U of T research finds glycine could be key to REM Sleep Behavior Disorder
2. New intranasal influenza vaccine triggers robust immunity with significantly less antigen
3. Nanoemulsion-Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen
4. Expert Says Conseco Trust May Significantly Alter The Senior Health Care Market
5. New EPA Lead Standard Significantly Improved to Protect Kids Health
6. Estimate of Annual HIV Incidence Increases Significantly; New Estimate Will Show Need For a National AIDS Strategy
7. On-X Life Technologies Significantly Reduces Study Management Costs with TEMPO from Clinipace
8. New study shows calcium significantly improves childrens bone health
9. Study: Global Business Performance Significantly Improved Through Project Management
10. Hibernation-on-demand drug significantly improves survival after extreme blood loss
11. Combining radiation and surgery significantly improves survival for head and neck cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 1Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 2Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 3Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 4Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 5Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 6Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 7Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 8Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 9Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 10Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 11ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 1ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 2ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 3Regence Wins Awards for Consumer Appeal to Transform Health Care 53156 1Regence Wins Awards for Consumer Appeal to Transform Health Care 53156 2